摘要
目的探讨补充阿法骨化醇对甲状腺自身免疫状态的影响。方法选取2013年6月-2015年3月就诊的未经治疗的甲状腺自身免疫患者[血清抗甲状腺过氧化物酶抗体（TPOAb）〉34μIU/ml,即单纯TPOAb阳性],根据TPOAb水平分为TPOAb〈500μIU/ml组、TPOAb 500~1 000μIU/ml组及TPOAb〉1 000μIU/ml组,每组再依据阿法骨化醇给药剂量分为0.5μg组和1.0μg组,每3个月测定1次患者的甲状腺功能水平（TSH、FT3、FT4）和TPOAb水平,共12个月。结果阿法骨化醇可以降低TPOAb水平,且0.5μg组和1.0μg组相比,TPOAb水平下降例数无统计学差异（P〉0.05）;3个不同TPOAb水平组相比,TPOAb水平下降例数差异无统计学意义（P〉0.05）。结论自身免疫性甲状腺疾病（AITD）补充阿法骨化醇可能有助于降低血清甲状腺自身抗体TPOAb水平,抑制甲状腺自身免疫反应的作用。
Objective Investigate the effect of Alfacalcidol has on Thyroid Autoimmunity State. Methods Select un- treated patients with autoimmune thyroid disease in hospital from July,2013 to March, 2015 （TPOAb 〉 34μIU/ml, ie. purely TPOAb positive ）. Divide the sample TPOAb into tthree groups： TPOAb 〈 500μIU/ml, TPOAbS00 ~ 1 000μIU/ml and TPOAb 〉 1 000μIU/ml. Each group taking Alfacalcidol capsules 0.5 μg/group and1.0 μg/group for 12 months, then detecting TPOAb.FT3 、FT4 levels in their serum. Results Alfacalcido] lowers TPOAh,with no significant differences between 0.5μg/ group and1.0μg,/group（P 〉 0.05）o In addition,in TPOAb 〈 500 pJU/m group ,TPOAbS00 ~ 1 000μIU/ml group and TPO- Ab 〉 1 000 group, TPOAb in patients who take Alfacalcido] goes down with no significant differences in decreasing ratio （ P 〉 0. 05）. Conclusion The supplement of Alfaealcidol in autoimmune thyroid disease patients probably may help to reduce thy- roid autoantibodies and inhibit the thyroid autoimmune response.
出处
《临床合理用药杂志》
2015年第23期25-26,28,共3页
Chinese Journal of Clinical Rational Drug Use
基金
徐州市科技项目(No:XZZDY1307)
